Biochemical Pharmacology volume 79, issue 8, P1108-1117 2010 DOI: 10.1016/j.bcp.2009.12.002 View full text
|
|
Share
Giovanni Luca Beretta, Valentina Benedetti, Giacomo Cossa, Yehuda G.A. Assaraf, Eran Bram, Laura Gatti, Elisabetta Corna, Nives Carenini, Donato Colangelo, Stephen B. Howell, Franco Zunino, Paola Perego

Abstract: ABSTRACTPt compounds still represent the mainstay of the treatment of ovarian carcinoma. The aim of the present study was to investigate the molecular bases of resistance to Pt drugs using an oxaliplatin-resistant ovarian carcinoma cell model IGROV-1/OHP. These cells exhibited high levels of resistance to oxaliplatin, cross-resistance to cisplatin and topotecan and displayed a